View Related Items
Category 6 - PATHOLOGY SERVICES
PN.0.27
Germline BRCA gene mutation tests (Items 73295, 73296, 73304 and 73333)
Patients who are found to have any form of affected allele should be referred for post-test genetic counselling as there may be implications for other family members. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral.
Related Items
Category 6 - PATHOLOGY SERVICES
73295 - Additional Information
Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with advanced (FIGO III-IV) high-grade serous or high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible, requested by a specialist or consultant physician, to determine eligibility for olaparib under the Pharmaceutical Benefits Scheme (PBS)
Maximum of one test per patient’s lifetime
Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,112.10
(See para PN.0.27 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73296 - Additional Information
Characterisation of germline gene variants:
(a) including copy number variation in:
(i) BRCA1 genes; and
(ii) BRCA2 genes; and
(iii) one or more of the genes STK11, PTEN, CDH1, PALB2 and TP53; and
(b) in a patient:
(i) with breast, ovarian, fallopian tube or primary peritoneal cancer; and
(ii) for whom clinical and family history criteria (as assessed, by the specialist or consultant physician who requests the service, using a quantitative algorithm) place the patient at greater than 10% risk of having a pathogenic or likely pathogenic gene variation identified in one or more of the genes specified in subparagraphs (a)(i), (ii) and (iii);
requested by a specialist or consultant physician
Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,112.10
(See para PN.0.27 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73304 - Additional Information
Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for olaparib under the Pharmaceutical Benefits Scheme.
Applicable once per lifetime
Fee: $1,000.00 Benefit: 75% = $750.00 85% = $912.10
(See para PN.0.27 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73333 - Additional Information
Detection of germline mutations of the von Hippel-Lindau (VHL) gene:
(a) in a patient who has a clinical diagnosis of VHL syndrome and:
(i) a family history of VHL syndrome and one of the following:
(A) haemangioblastoma (retinal or central nervous system);
(B) phaeochromocytoma;
(C) renal cell carcinoma; or
(i) 2 or more haemangioblastomas; or
(ii) one haemangioblastoma and a tumour or a cyst of:
(A) the adrenal gland; or
(B) the kidney; or
(C) the pancreas; or
(D) the epididymis; or
(E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or
(a) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome:
(i) haemangioblastomas of the brain, spinal cord, or retina;
(ii) phaeochromocytoma;
(iii) functional extra-adrenal paraganglioma
Fee: $600.00 Benefit: 75% = $450.00 85% = $512.10
(See para PN.0.27 of explanatory notes to this Category)
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change